By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news originating from Chicago, Illinois, by NewsRx correspondents, research stated, "Antisense oligonucleotides (oligos) have been employed against prostate cancer models in both in vivo and in vitro systems. While most target growth factors or their receptors, other oligos are directed against inhibitors of apoptosis or mediators of androgen action."
Our news journalists obtained a quote from the research from the University of Illinois, "Those which suppress bcl-2 activity (in prostate cancer patients) have even reached clinical trials. We evaluated a set of oligos which targeted and comparably suppressed the expression of bcl-2, an apoptosis inhibitory protein. Our first study reported that LNCaP cells were adapted by suppression of caspase-3 (a promoter of apoptosis). In this study we evaluated additional proteins associated with tumor progression and found the expression of the androgen receptor, its p300 and IL-6 co-activators, as well as v-myc (oncogenic) and (unexpectedly) tumor suppressor p53 genes to be enhanced. We conclude that oligo treatment directed against bcl-2, intended to stimulate apoptosis, can be evaded through compensatory changes in gene activity associated with additional regulators of apoptosis, androgen sensitivity and oncogenesis."
According to the news editors, the research concluded: "This suggests that therapeutic suppression of bcl-2 can promote tumor resistance and transformation to a more aggressive (androgen and oncogene driven) phenotype."
For more information on this research see: Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3. Medical Oncology, 2013;30(3):562-570. Medical Oncology can be contacted at: Humana Press Inc, 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA. (Springer - www.springer.com; Medical Oncology - www.springerlink.com/content/1357-0560/)
The news correspondents report that additional information may be obtained from M. Rubenstein, University of Illinois, Dept. of Urol, Chicago, IL 60612, United States. Additional authors for this research include C.M.P. Hollowell and P. Guinan (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Chicago, Illinois, Genetics, p53 Gene, United States, Effector Caspases, Cysteine Proteases, Peptide Hydrolases, Cancer Gene Therapy, Enzymes and Coenzymes, Cysteine Endopeptidases, North and Central America, Clinical Trials and Studies, Apoptosis Regulatory Proteins
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC